Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR - Free Report) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $60.00 price objective on the biotechnology company's stock.

A number of other research analysts also recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, January 23rd. Sanford C. Bernstein cut their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating on the stock in a research report on Friday, November 29th. Citigroup cut their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 27th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. Finally, Piper Sandler cut their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Trading Up 4.3 %

Shares of ARWR traded up $0.82 during midday trading on Tuesday, hitting $19.93. The stock had a trading volume of 558,701 shares, compared to its average volume of 2,257,125. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $36.72. The firm has a market cap of $2.49 billion, a PE ratio of -3.98 and a beta of 0.95. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The stock's 50 day moving average is $20.08 and its 200 day moving average is $21.22.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). As a group, analysts forecast that Arrowhead Pharmaceuticals will post -3.4 EPS for the current fiscal year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 27,167 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.83, for a total transaction of $538,721.61. Following the completion of the sale, the chief financial officer now directly owns 473,433 shares in the company, valued at approximately $9,388,176.39. The trade was a 5.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director William D. Waddill sold 3,748 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the sale, the director now owns 44,125 shares of the company's stock, valued at approximately $966,337.50. The trade was a 7.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 147,432 shares of company stock worth $2,957,986 in the last three months. Corporate insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. R Squared Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $38,000. Values First Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $52,000. Van ECK Associates Corp increased its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 1,250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock valued at $88,000 after purchasing an additional 788 shares in the last quarter. Finally, KBC Group NV increased its holdings in shares of Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 1,644 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.